Market Research Logo

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis out licensed the commercial rights of Envarsus MENA region, Canada and China. The company sells ENVARSUS XR to wholesalers, specialty pharmacies and other customers. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

May 14,2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Apr 13,2018: Veloxis Pharmaceuticals - Passing of Annual General Meeting 2018
Apr 03,2018: Veloxis Appoints Morten Marott as Chief Financial Officer
Feb 27,2018: Veloxis Pharmaceuticals Releases Annual Report for 2017
Feb 14,2018: Veloxis Secures $60M in Debt Financing

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Veloxis Pharmaceuticals A/S - Key Facts
Veloxis Pharmaceuticals A/S - Key Employees
Veloxis Pharmaceuticals A/S - Key Employee Biographies
Veloxis Pharmaceuticals A/S - Major Products and Services
Veloxis Pharmaceuticals A/S - History
Veloxis Pharmaceuticals A/S - Company Statement
Veloxis Pharmaceuticals A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Veloxis Pharmaceuticals A/S - Business Description
Veloxis Pharmaceuticals A/S - Corporate Strategy
Veloxis Pharmaceuticals A/S - SWOT Analysis
SWOT Analysis - Overview
Veloxis Pharmaceuticals A/S - Strengths
Veloxis Pharmaceuticals A/S - Weaknesses
Veloxis Pharmaceuticals A/S - Opportunities
Veloxis Pharmaceuticals A/S - Threats
Veloxis Pharmaceuticals A/S - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Veloxis Pharmaceuticals A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Apr 13, 2018: Veloxis Pharmaceuticals - Passing of Annual General Meeting 2018
Apr 03, 2018: Veloxis Appoints Morten Marott as Chief Financial Officer
Feb 27, 2018: Veloxis Pharmaceuticals Releases Annual Report for 2017
Feb 14, 2018: Veloxis Secures $60M in Debt Financing
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Veloxis Pharmaceuticals A/S, Key Facts
Veloxis Pharmaceuticals A/S, Key Employees
Veloxis Pharmaceuticals A/S, Key Employee Biographies
Veloxis Pharmaceuticals A/S, Major Products and Services
Veloxis Pharmaceuticals A/S, History
Veloxis Pharmaceuticals A/S, Subsidiaries
Veloxis Pharmaceuticals A/S, Key Competitors
Veloxis Pharmaceuticals A/S, Ratios based on current share price
Veloxis Pharmaceuticals A/S, Annual Ratios
Veloxis Pharmaceuticals A/S, Annual Ratios (Cont...1)
Veloxis Pharmaceuticals A/S, Interim Ratios
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Veloxis Pharmaceuticals A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Veloxis Pharmaceuticals A/S, Performance Chart (2013 - 2017)
Veloxis Pharmaceuticals A/S, Ratio Charts
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report